JPRN-jRCT1052230085招募中2 期
A Phase II Study to Evaluate the Efficacy and Safety of Deep-Inspiration Breath-Hold Daily Adaptive Radiotherapy in Centrally Located Lung Tumors - PUDDING-STUDY
Takashi Mizowaki0 个研究点目标入组 25 人开始时间: 2023年8月12日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1) Patients aged 20 years or older
- •2) Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- •3) Central lung tumors 5 cm or less (central lung tumor is defined according to IASLC recommendations: located 2 cm or less from mediastinum, including bronchus, esophagus, heart, brachial plexus, vessels, spinal cord, phrenic nerve, and recurrent laryngeal nerve)
- •4) Ability to hold breath for at least 20 seconds
- •5) Indicated for stereotactic body radiotherapy or hypofractionated radiotherapy by a radiation oncologist.
- •6) Written informed consent to participate in the study is obtained
排除标准
- •1) Patients with interstitial pneumonia
- •2) who are not expected to live 3 months or longer, according to the physician
- •3) who are unable to consent to participate in the study
研究者
相似试验
进行中（未招募）
1 期
Evaluation of efficacy and safety of MEDI2070 in patients with active, moderate-to-severe Crohn's disease.MedDRA version: 19.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersCrohn's DiseaseEUCTR2012-004098-26-DEAstraZeneca AB120
进行中（未招募）
1 期
Evaluation of efficacy and safety of MEDI2070 in patients with active, moderate-to-severe Crohn's disease.MedDRA version: 14.1Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersCrohn's DiseaseEUCTR2012-004098-26-CZAstraZeneca AB120
进行中（未招募）
1 期
Evaluation of efficacy and safety of MEDI2070 in patients with active, moderate-to-severe Crohn's disease.MedDRA version: 18.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersCrohn's DiseaseEUCTR2012-004098-26-FRAstraZeneca AB121
进行中（未招募）
1 期
Evaluation of efficacy and safety of MEDI2070 in patients with active,moderate-to-severe Crohn's disease.Crohn's DiseaseEUCTR2012-004098-26-ITASTRAZENECA120
进行中（未招募）
1 期
Evaluation of efficacy and safety of MEDI2070 in patients with active, moderate-to-severe Crohn´s disease.EUCTR2012-004098-26-ESAstraZeneca AB120